 
N
 
 
BS
PJ
Da
M
Sc
 
De
 
Su
 
Pl
ye
 
Th
 
 
 
T
h
 
 
Y
o
Fo
    
Jit
Co
 
 
 
 
 
 
 
ovember 1
SE Limited
J. Towers,  
alal Street 
Mumbai-400
cript Code
ear Sir/Ma
ub.: Press r
lease find a
ear ended 3
his is for yo
hanking yo
ours faithfu
or Wanbur
                   
tendra J. G
ompany S
18, 2025 
d 
 
 
0001 
: 524212 
adam, 
release on 
attached h
30th Septem
our inform
ou. 
ully,  
ry Ltd  
                   
Gandhi 
ecretary 
 Q2 & H1 
herewith co
mber, 2025
mation and 
           
Na
Exc
Ban
Mu
Scr
 
FY26 Fina
opy of pre s
. 
 record. 
 
ational Stoc
change Pla
ndra (East)
umbai -400
ript Code: 
ncial Resu
ss release o
 
ck Exchang
aza, Bandra
),  
0051 
 WANBUR
ults 
on Financi
ge of India
a Kurla Co
RY 
ial Results
a Ltd, 
omplex, 
 for the q u
uarter and 
 
 half 
 

PA
 
14
th
fo
 
Q
P
R
O
E
E
P
P
*inc
 
Fi
Fo
 
 
 
 
 
 
Fo
 
 
 
 
 
AT jump
4th Novem
he global A
r the quart
Q2 & H1 FY
Particulars 
Revenue fr
Operations
EBITDA* 
EBITDA M
PAT 
PAT Margi
cl. other income 
inancial Hi
or the quar
Revenue f
EBITDA (
in Q2 FY2
EBITDA M
PAT for t
growth of
PAT Marg
or half yea
Revenue 
reflecting 
EBITDA (
FY25, re g
yield. 
EBITDA M
PAT for H
216.6% led
PAT Marg
Wanb
ps 216.6%
im
ber, 2025,  
API marke t
ter and hal
Y26 Finan
  
rom 
s 
Margin (%) 
in (%) 
ighlights: 
rter ended
from operat
(including o
25, registerin
Margin stoo
the quarter 
f 89.3% led 
gin stood at
ar ended as
from oper a
 a YoY grow
(including o
gistering a g
Margin stoo
H1 FY26 sto
d by volum
gin stood at
bury De
% YoY to R
mproved 
 MUMBA
t and do m
lf year end
ncial High
Q2 FY2
160.1 
26.0 
16.2%
15.2 
9.5% 
 
d as on 30th
tions stood 
other incom
ng a growth
od at 16.2% 
stood at R s
by cost effic
t 9.5% for Q
s on 30th Se
ations for H
wth of 10.6%
other incom
growth of 5
od at 15.7% 
ood at Rs. 28
me growth, c
t 8.9% for H
elivers R
Rs.28.7 C
 Product 
AI: Wanbur
mestic bra n
ded 30th Sep
hlights:    
26 Q2 FY25
 161.2 
21.6 
 13.3%  
8.0 
 4.9% 
h Septembe
 at Rs. 160.1
me) for the q
h of 20.1% l
 compared t
s. 15.2 cror e
ciencies, im
Q2FY26 com
eptember 
H1 FY26 st o
%, led by vo
me) for H1 F
51.3% led b
 compared t
8.7 crore, co
cost efficien
H1 FY26 com
 
Robust H
Cr, driven
 yield an
ry Ltd, a p
nded form u
ptember, 2
              
5 Y-o-Y Q
(0.7%) 
20.1% 
292 bps 
89.3% 
455 bps 
er 2025 
1 crore, com
quarter stoo
led by cost e
to 13.3% in 
e, compared
mproved Pro
mpared to 4.
2025 
ood at Rs. 3
olume grow
FY26 stood a
by revenue 
to 11.4% in 
ompared to
ncies, impro
mpared to 3
H1 FY26
n by volu
nd lower f
pharmaceu
ulations, h
2025. 
Q1 FY26 Q
163.2 
24.8 
15.2% 1
13.5 
8.2% 1
mpared to Rs
od at Rs. 26.
efficiencies 
 Q2FY25. 
d to Rs. 8.0  
oduct yield 
9% for Q2 F
323.2 crore,  
wth. 
at Rs.50.8 cr
growth, c o
 H1 FY25 
 Rs. 9.1 cror
ved Produc
3.1% for H1 
6 Perfor
ume grow
finance c
utical com p
has annou n
Q-o-Q H1
(1.9%) 3
4.8% 
105 bps 1
12.5% 
122 bps 8
s.161.2 cror
.0 crore, as 
 & improve
 crore in Q 2
& lower fin
FY25 
 up from R
rore, compa
ost efficienc
re in H1 FY
ct yield and
 FY25 
rmance 
wth, cost e
cost 
pany wit h
nced its fi n
        (Rs i
1 FY26 H1 
323.2 2 9
50.8 3
5.7% 1 1
28.7 9
8.9% 3.
e in Q2FY25
compared t
d Product y
2FY25, regis
nance cost. 
Rs. 292.3 cr o
ared to Rs. 3
ies and im p
Y25, register
d lower finan
efficienc
h a presen c
nancial re s
in Crore)  
 FY25 Y-o
92.3 10.6
33.6 51.3
1.4% 430 
9.1 216.
.1% 578 
5 
to Rs. 21.6 c
yield. 
stering a r o
ore in H1 F
33.6 crore in
proved Pr o
ring a grow
nce cost 
 
ies, 
ce in 
sults 
                  
o-Y 
6% 
3% 
bps 
.6% 
bps  
crore 
obust 
FY25, 
n H1 
oduct 
wth of 
 
  
 
Co
 
“
Q
(13
bp
a r
Th
so
th
K
S
 
T
h
ne
th
 
Th
a s
tra
 
W
gr
qu
ph
 
Ab
Es
BS
br
Fo
(A
 
Th
M
in
In
an
in
 
 
ommenting
Q2 continu e
3.3%) crore
ps of revenu
robust grow
 
his improvem
lvent recov
rough aucti
SM. 
he Company
ew brand (C
rough targe
he recent im
significant 
ansparency,
With our C A
rowth, incre
uality and c
harmaceutic
bout Wanb
stablished 
SE Ltd (Co
randed F o
ormulation
Andhra Pra
he API p
Mefenamic 
nclude som
n formulati
nd cold 
nflammator
g on the pe
es to be st r
e in Q2 FY2
ues. Further,
wth of appro
ment was d
veries. Addi
ion-based so
y’s Formula
C-red-advan
eted training
mplementati
 milestone i
, and data-d
APEX plan 
easing capac
compliance.
cal partner w
bury Ltd. 
in 1988, li s
ode: 524212
ormulation 
n presenc e
adesh) and
product p o
acid, Par o
me of the lea
ons, the co
solutions, 
ry, & analg
erformance
ronger wit h
25, register
r, achieved P
ox. 90 % led
driven by sev
tionally, co
ourcing for
ations busin
nced liposom
g of the sale
on of the SA
n our digi t
driven decis
on its way  f
cities, susta
 Our effor t
while drivin
sted on th e
2). The com
 with its 
e. The co m
d Patalgang
ortfolio i n
oxetine a n
ading glob
ompany ha
 gynaeco
gesics.   
e, Mr. Moh
h EBITDA 
ing a growt
PAT of ₹ 15
d by cost effi
veral techni
ontributed b
r large-volu
ness turned
mal iron sup
es force and
AP S/4HAN
tal transform
sion-making
 for introdu
aining opera
ts are aime d
ng long-term
e National
mpany has
API bein g
mpany ha s
ga (Mahara
ncludes: M
nd variou s
bal generic 
as a wide p
ology, or t
 
han Rayana
achievemen
th of 20% o
5.2 crore as 
ficiencies, im
ical initiativ
by procurem
me raw m a
d EBITDA p
pplement), o
d various bra
NA Private
mation jour
g across the 
uction of ne w
ational effic
d at stren g
m value for 
l Stock Ex c
s a strong p
g exporte d
s USFDA  
ashtra). 
Metformin,
s other p r
 players. 
presence ac
thopaedics
a, Director
nt of ₹ 26.0
over previou
 compared t
mproved Pro
ves includin
ment efficien
aterials and 
positive sup
overall impr
and promot
e Cloud und
rney. This w
 organizatio
w products
ciencies and
gthening W
 all stakehol
change of I
presence in
d to over  
 & EUG M
, Sertrali n
roducts i n
cross major
s, nutrac e
r of Wanbu
0 (16.2%) c
us quarter, o
to ₹ 8.0 cro
oduct yield 
ng enhanced
ncies—suc h
 longer peri
pported by t
roved field p
tion activitie
der the Rise 
will enable 
on. 
s, we remai n
d maintainin
Wanbury’s p
lders.” 
India Ltd 
n API glob
 50 coun t
MP appro v
ne, Tram a
n pipeline.  
r therapeu
euticals, g
ury Ltd., sa
crore as co m
overall impr
re in Q2 FY
 & lower fin
d product y
h as impro v
iod supplier
the successf
productivity
es. 
 with SAP 
 greater agil
n committe
ng the high
position as a
(Code: WA
bal market
tries and 
ved facilit i
adol, Dip h
 The co m
utic categor
gastro in t
aid,  
mpared to ₹
rovement of
Y25, registe
nance cost. 
yields and hi
ved negotiat
rs’ contract
ful launch o
y across Br
 initiative m
lity, operati
d to sustai n
hest standar
a trusted g
ANBURY) 
t and dome
has Pa n-In
ies at Ta n
henhydram
mpany's cl i
ries like, co
testinal, a
 
₹21.6 
f 292 
ering 
igher 
tions 
ts for 
of the 
rands 
marks 
ional 
nable 
rds of 
global 
 and 
estic 
ndia 
nuku 
mine, 
ients 
ough 
anti-

 
 
Fo
 
 
Fo
 
 
Jit
Co
W
BS
Se
Va
M
Te
Em
 
 
Di
 
Th
be 
ca
un
pr
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or more de
or further i
tendra J. Ga
ompany Sec
Wanbury Lim
SEL Techpa
ector 30-A, O
ashi, Navi M
aharashtra,
el: +91-22-67
mail: jitendr
isclaimer: 
his documen
 construed 
use actual  
ncertainties 
ressures, com
etails on W
informatio
andhi 
cretary, 
mited 
rk, B -Wing
Opp. Vashi 
Mumbai - 40
, India. 
794 2222 
ra.gandhi@w
 
nt may cont
 as forward-
 results to  
 include fa c
mpetition an
Wanbury Lt
on please c
g, 10th Floor
 Railway Sta
00703,  
wanbury.co
tain stateme
-looking sta
 differ ma t
ctors such 
nd regulato
td.: https://
contact: 
r, 
ation, 
om 
ents which 
atements. T
terially fro m
as general  
ory developm
 
//www.wan
Ha
Ad
Oa
Ha
Lo
Mu
Tel
Em
sm
 reflect man
The future in
m the curr e
 economic c
ments. 
nbury.com
anishi Shah
dfactors PR
asis Compl e
all, Pandura
wer Parel W
umbai – 400
l: +91 96190
mail: hanish
mit.shah@ad
agement’s c
nvolves cert
ent views 
conditions, f
m/ 
h / Smit Sha
 
ex, Kamal a
ang Budhka
West, 
0 021. 
059339 / +9
hi.shah@adfa
dfactorspr.co
current view
tain risks an
being exp r
foreign ex c
ah  
a Mills Co m
ar Marg,  
91 987078959
actorspr.com
om 
ws and estim
nd uncertai
ressed. Pot e
change fluc t
mpound, C
96 
m 
mates and c
inties and c
ential risks  
tuation, pr i
 
City 
could 
could 
 and 
icing 
 

